Department of Pediatrics, Division of Neonatology, Gaziantep University, Osmangazi Mahallesi, Üniversite Blv., 27310 Şehitkamil, Gaziantep, Turkey.
Department of Pediatrics, Division of Pediatric Cardiology, Diyarbakir Children's Diseases Hospital, Diyarbakir, Turkey.
Eur J Pediatr. 2019 Jun;178(6):829-836. doi: 10.1007/s00431-019-03361-4. Epub 2019 Mar 20.
Several recent studies have reported that toxic metabolites accumulated in the body as a product of inborn errors of metabolism (IEM) are eliminated more rapidly with continuous venovenous hemodiafiltration (CVVHDF) than with peritoneal dialysis (PD). However, there is still uncertainty about the impacts of dialysis modalities on the short-term outcome. Here, it was aimed to investigate the effects of dialysis modalities on the short-term outcome. This retrospective study included 40 newborn infants who underwent PD (29 patients) or CVVHDF (11 patients) due to inborn errors of metabolism at a tertiary centre, between June 2013 and March 2018. The outcomes and the potential effects of the dialysis modality were evaluated. Of 40 patients, 21 were urea cycle defect, 14 were organic academia, and 5 were maple syrup urine disease. The median 50% reduction time of toxic metabolites were shorter in patients treated with CVVHDF (p < 0.05). Catheter blockage was the most common complication observed in PD group (24.1%), whereas in CVVHDF group hypotension and filter blockage were more common. There was no significant difference in mortality between dialysis groups (38% vs. 45.4%, p > 0.05). In patients with hyperammonaemia, duration of plasma ammonia > 200 μg/dL was the most important factor influencing mortality (OR 1.05, CI 1.01-1.09, p = 0.007).Conclusion: This study showed that CVVHDF is more efficient than PD to rapidly eliminate toxic metabolites caused by IEM in newborn infants, but not in improving survival. What is Known: •Toxic metabolites are eliminated more rapidly with CVVHDF than with PD. •Higher complication rates were reported with rigid peritoneal catheters in PD and catheter blockage in CVVHDF. What is New: •Prolonged duration of plasma ammonia levels above a safe limit (200 μg/dL) was associated with increased mortality. •Lower catheter-related complication rates may have been associated with the use of Tenckhoff catheters in PD and the use of right internal jugular vein in CVVHDF.
最近的几项研究报告称,与腹膜透析(PD)相比,连续静脉-静脉血液透析滤过(CVVHDF)可更快速地清除因先天性代谢错误(IEM)而在体内积累的毒性代谢物。然而,透析方式对短期结果的影响仍存在不确定性。在这里,我们旨在研究透析方式对短期结果的影响。这项回顾性研究纳入了 2013 年 6 月至 2018 年 3 月期间,在一家三级中心因代谢错误而接受 PD(29 例)或 CVVHDF(11 例)治疗的 40 例新生儿患者。评估了结局和透析方式的潜在影响。40 例患者中,21 例为尿素循环缺陷,14 例为有机酸血症,5 例为枫糖尿症。接受 CVVHDF 治疗的患者毒性代谢物的 50%减半时间更短(p<0.05)。PD 组最常见的并发症是导管堵塞(24.1%),而 CVVHDF 组低血压和过滤器堵塞更为常见。两组死亡率无显著差异(38% vs. 45.4%,p>0.05)。在高氨血症患者中,血浆氨水平>200μg/dL 的持续时间是影响死亡率的最重要因素(OR 1.05,95%CI 1.01-1.09,p=0.007)。结论:本研究表明,CVVHDF 比 PD 更有效地快速清除新生儿 IEM 引起的毒性代谢物,但不能改善生存率。已知内容:•与 PD 相比,CVVHDF 更能迅速清除因 IEM 而在体内积累的毒性代谢物。•PD 中刚性腹膜导管的并发症发生率较高,CVVHDF 中导管堵塞的并发症发生率较高。新内容:•血浆氨水平高于安全限制(200μg/dL)的持续时间与死亡率增加相关。•PD 中使用 Tenckhoff 导管和 CVVHDF 中使用右颈内静脉可能与较低的导管相关并发症发生率相关。